The Epic Sciences team attended the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1st - 5th, 2018.
The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E). Author: Andrew J. Armstrong, MD • June 4, 2018, Hall D1, 4:12 PM - 4:24 PM
Board 165 - Analysis of circulating tumor cells (CTCs) in patients across multiple metastatic breast cancer (mBCa) cohorts identifies marked inter- and intra- patient heterogeneity in CTC size, shape, and overall morphology. Author: Gordon Vansant, PhD • June 2, Hall A, 8:00 AM – 11:30 AM
Board 239 - Phenotypic and genomic characterization of CTCs as a biomarker for prediction of veliparib therapy benefit in mCRPC. Author: Ryan Dittamore, MBA • June 2, Hall A, 1:15 PM – 4:45 PM
- Discussion June 2, S406, 4:45 PM - 6:00 PM
Board 280 - Unique patterns of the selection and changing in circulating tumor cell (CTC) phenotypes and genotypes by the drug class in metastatic castration-resistant prostate cancer (mCRPC). Author: Howard I. Scher, MD • June 2, Hall A, 1:15 PM – 4:45 PM
Board 281 - Clonal concordance and genomic heterogeneity in single CTC copy number alterations vs. paired IMPACT metastatic tissue sequencing from mCRPC patient samples. Author: Howard I. Scher, MD • June 2, Hall A, 1:15 PM – 4:45 PM